Titan Spine Endoskeleton TT/TO Study

A Prospective Investigation Comparing Bone Graft Extenders in Transforaminal Interbody Fusions (TLIF) With an Acid Etched Titanium Implant: A Clinical Outcomes and Cost Analysis

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03910309

Enrollment

Registered

2019-04-10

Start date

2015-01-31

Completion date

2018-09-30

Last updated

2019-04-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Degenerative Disc Disease, Spondylolisthesis

Keywords

degenerative disc disease, spondylolisthesis

Brief summary

This is a prospective, multi-center controlled observational clinical study. All subjects will receive Titan Endoskeleton TT/TO acid etched titanium implant for the planned procedure. Each site will have a predetermined bonegraft extender to be used in all enrolled subjects at that site.

Interventions

DEVICETLIF with Titan TT/TO interbody cage

fusion surgery

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

1. Be 18-75 years of age, and skeletally mature 2. Have clinical and radiological evidence of degenerative disc disease at one or two levels of the lumbar spine between L2-S1. May also have spondylosis, spinal stenosis, or spondylolisthesis at these levels. 3. In the opinion of the treating surgeon, must already be a qualified candidate for lumbar fusion surgery including 6 months of conservative care prior to surgical intervention. 4. Psychosocially, mentally and physically able to comply with protocol, post-operative management and follow-up schedule. 5. Subject must understand and sign the written Informed Consent.

Exclusion criteria

1. Previous history of fusion surgery at the index level(s). 2. Clinical, laboratory and/or radiological evidence of back pain secondary to acute or chronic infection, malignancy, other space occupying lesions and metabolic bone demineralization diseases (e.g. osteomalacia, gout, Paget's disease etc.) 3. Osteoporosis defined as a DEXA bone density measurement T score ≤ 2.5 (Necessity for DEXA scan will be determined by investigator's standard of care) 4. Any terminal or autoimmune disease including but not limited to HIV infection, rheumatoid arthritis or lupus. 5. Any other concurrent medical disease that might impair normal healing process. 6. Morbid obesity (BMI ≥ 40 kg/m2). 7. Investigational drug or device use within 30 days. 8. Currently a prisoner. 9. Currently experiencing a major mental illness (psychosis, schizophrenia, major affective disorder) which may indicate that the symptoms are psychological rather than of physical origin. \-

Design outcomes

Primary

Measure	Time frame	Description
Pain measured by VAS	2 years	1 to 10
Function measured by oswestry disability index	2 years	10 question score

Secondary

Measure	Time frame	Description
Success of fusion	3 months, 6 months, 12 months, 24 months	Fusion will be assessed by AP/Lat Flex/Ext radiographs

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026